SHOULDER INNOVATIONS INC

Gilde Healthcare’s recent sell‑off of 1,196 shares of Shoulder Innovations shows a steady rebalancing, not a price shock.

Gilde Healthcare trims 7,338 shares of Shoulder Innovations at $22.64, raising concerns about the stock’s short‑term direction amid strong Q2 growth.

How Gilde’s insider sales of SIII shares impact buy‑back confidence, market volatility, and long‑term upside for an orthopedics innovator.

Insightful look at SHOULDER INNOVATIONS insider sales in the booming health‑tech sector—why Rule 10b‑5‑1 trades matter, what they reveal about growth, and how investors should stay tuned.

Shoulder Innovations’ CEO buys 10,000 shares at a 90% discount—showing confidence in a big capital raise that will fund its promising TS‑A1, S‑CAR and B‑Net therapies.

Insider buying signals confidence in Shoulder Innovations, but governance vote could sway price—discover the risks and upside of CFO S.’s strategy.

CEO buys 12k shares of Shoulder Innovations at a deep discount—signaling management confidence amid a rally‑up, clinical milestones, and market volatility.